

# Report to Board of Directors

For Information

## Finance Report April 2022 (Month 1), FY23

### Contents

#### Executive Summary

1. Income Statement
2. Clinical Income
3. Non-Clinical Income
4. Agency
5. Cost Improvement Plan
6. Statement of Position
7. Cash-flow
8. Working Capital Indicators
9. Capital Investment Programme
10. Reconciliation to NHSI Template

*A risk assessment has been undertaken around the legal issues that this paper presents and there are no issues that need to be referred to the Trust Solicitors.*

## Executive Summary

|                       | Month 1                              |
|-----------------------|--------------------------------------|
| EBITDA performance    | £1.5m surplus, £0.3m adverse to plan |
| I&E performance       | £0.7m surplus, £0.2m adverse to plan |
| Cost Improvement Plan | £0.3m, £0.4m adverse to plan         |
| Cash                  | £84.6m, breakeven to plan            |

- The month 1 I&E position is a **£0.7m** surplus, **£0.2m** adverse to plan. EBITDA is a **£1.5m** surplus, **£0.3m** adverse to plan.
- The FY23 plan would have been for a breakeven position, however, the plan submitted to NHSE is for **£9.2m** deficit due to two outstanding contractual issues: - with NHSE Spec Comm (**£3.5m**) and BOB MHIS (**£5.7m**).
- I&E is **£0.2m** adverse to plan driven by under delivery of CIP **£0.4m**, continuation of high level of agency and contracted OAPS (**c.£1.6m**) both reported as Covid spend in FY22, partially mitigated by release of covid funding **c.£0.6m** in expectation of the tapering down of these expenditure items and release of reserves and deferred income, **c.£1.2m**.
- The CIP plan for the year is £7.9m with delivery profiled evenly over 12 months. **£0.3m** has been delivered at month 1, this is **£0.4m** adverse to plan due to delay in CIP engagement as a result of Covid-19.
- The closing cash position at the end of April was **£84.6m**.

### Recommendation:

The Board of Directors are asked to note the Finance Report against plan and seek any further assurances as required.

# 1. Income Statement

| INCOME STATEMENT |             |               |                                  |             |             |              |                |             |              |              |                |   |
|------------------|-------------|---------------|----------------------------------|-------------|-------------|--------------|----------------|-------------|--------------|--------------|----------------|---|
| YTD Actual M1    | Prior Year  |               |                                  |             | Month 1     |              |                |             | Year-to-Date |              |                |   |
|                  | £m          | Change<br>£m  | %                                |             | Plan<br>£m  | Actual<br>£m | Variance<br>£m | %           | Plan<br>£m   | Actual<br>£m | Variance<br>£m | % |
| 30.7             | 8.0         | 25.9%         | Clinical Income                  | 38.3        | 38.6        | 0.3          | 0.0%           | 38.3        | 38.6         | 0.3          | 0.7%           |   |
| 5.5              | 1.3         | 23.6%         | Other Operating Income           | 4.9         | 6.8         | 1.9          | 0.0%           | 4.9         | 6.8          | 1.9          | 38.6%          |   |
| <b>36.2</b>      | <b>9.3</b>  | <b>25.6%</b>  | <b>Operating Income, Total</b>   | <b>43.3</b> | <b>45.4</b> | <b>2.2</b>   | <b>0.0%</b>    | <b>43.3</b> | <b>45.4</b>  | <b>2.1</b>   | <b>5.0%</b>    |   |
| 26.0             | -3.5        | -13.4%        | Employee Benefit Expenses (Pay)  | 26.2        | 29.5        | -3.3         | 0.0%           | 26.2        | 29.5         | -3.3         | -12.5%         |   |
| 9.2              | -5.2        | -56.5%        | Other Operating Expenses         | 15.3        | 14.4        | 0.9          | 0.0%           | 15.3        | 14.4         | 0.9          | 5.6%           |   |
| <b>35.2</b>      | <b>-8.7</b> | <b>-24.7%</b> | <b>Operating Expenses, Total</b> | <b>41.5</b> | <b>43.9</b> | <b>-2.4</b>  | <b>0.0%</b>    | <b>41.5</b> | <b>43.9</b>  | <b>-2.4</b>  | <b>-5.8%</b>   |   |
| 0.0              | 0.0         | 0.0%          | Non-Operational Income           | 0.0         | 0.0         | 0.0          | 0.0%           | 0.0         | 0.0          | 0.0          | 0.0%           |   |
| <b>1.0</b>       | <b>0.6</b>  | <b>59.9%</b>  | <b>EBITDA</b>                    | <b>1.8</b>  | <b>1.5</b>  | <b>-0.3</b>  | <b>0.0%</b>    | <b>1.8</b>  | <b>1.5</b>   | <b>-0.3</b>  | <b>-14.9%</b>  |   |
| 0.0              | 0.0         | 0.0%          | Profit/(Loss) on asset disposal  | 0.0         | 0.0         | 0.0          | 0.0%           | 0.0         | 0.0          | 0.0          | 0.0%           |   |
| 0.6              | 0.1         | 16.7%         | Depreciation and Amortisation    | 0.5         | 0.5         | 0.0          | 0.0%           | 0.5         | 0.5          | 0.0          | -1.8%          |   |
| 0.0              | 0.0         | 0.0%          | Asset Impairment                 | 0.0         | 0.0         | 0.0          | 0.0%           | 0.0         | 0.0          | 0.0          | 0.0%           |   |
| 0.1              | 0.1         | 138.9%        | Interest                         | 0.1         | 0.0         | 0.0          | 0.0%           | 0.1         | 0.0          | 0.0          | 61.7%          |   |
| 0.1              | 0.0         | 0.0%          | Other Finance Charge             | 0.1         | 0.1         | 0.0          | 0.0%           | 0.1         | 0.1          | 0.0          | -1.4%          |   |
| 0.2              | -0.1        | -59.5%        | PDC Dividend                     | 0.2         | 0.2         | 0.0          | 0.0%           | 0.2         | 0.2          | 0.0          | 8.6%           |   |
| <b>0.0</b>       | <b>0.7</b>  | <b>0%</b>     | <b>Surplus/ (Deficit)</b>        | <b>0.9</b>  | <b>0.7</b>  | <b>-0.2</b>  | <b>0.0%</b>    | <b>0.9</b>  | <b>0.7</b>   | <b>-0.2</b>  | <b>-23.7%</b>  |   |

The month 1 I&E position is a **£0.7m** surplus, **£0.2m** adverse to plan. EBITDA is a **£1.5m** surplus, **£0.3m** adverse to plan.

Excluding contractual issues with BOB (MHIS) & NHSE (Specialised commissioning) in total **£9.2m**. The FY23 plan is for a breakeven position which includes **£7.9m** CIP requirement and a requirement to reduce Covid expenditure by **£12.0m** as we progress through the year.

I&E is **£0.2m** adverse to plan driven by under delivery of CIP **£0.4m**, continuation of high level of agency and contracted OAPS (**c.£1.6m**) both reported as Covid spend in FY22 partially mitigated by release of covid funding **c.£0.6m** in expectation of the tapering down of these expenditure items and release of reserves and deferred income, **c.£1.2m**. The CIP plan for the year is **£7.9m** with delivery profiled evenly over 12 months. **£0.3m** has been delivered at month 1, this is **£0.4m** adverse to plan due to delay in CIP engagement as a result of Covid-19.

The I&E performance in FY23 is **£0.7m** better than in FY22 due to deferral of investment income in month 1 of FY22.

## Covid-19 Costs

**FY23 Directorate COVID Funding** **-7,318**

|  |       |                                       |
|--|-------|---------------------------------------|
| Correct Inpatient establishments - community | 712   | Per ME Review                         |
| Correct Inpatient establishments - MH        | 1,199 | Per ME Review                         |
| PPE & Testing Team                           | 646   | Retained as-is until further guidance |
| OOA Beds                                     | 1,399 | Phased downward                       |
| Additional staffing support                  | 2,518 | Phased downward                       |
| Additional cleaning                          | 834   | Retained as-is until further guidance |

**-10**

| <b>Profile:</b>                              | <b>M1</b>    | <b>M2</b>    | <b>M3</b>  | <b>M4</b>  | <b>M5</b>  | <b>M6</b>  | <b>M7</b>  | <b>M8</b>  | <b>M9</b>  | <b>M10</b> | <b>M11</b> | <b>M12</b> |              |
|--|--------------|--------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|--------------|
| Correct Inpatient establishments - community | 59           | 59           | 59         | 59         | 59         | 59         | 59         | 59         | 59         | 59         | 59         | 59         | <b>712</b>   |
| Correct Inpatient establishments - MH        | 100          | 100          | 100        | 100        | 100        | 100        | 100        | 100        | 100        | 100        | 100        | 100        | <b>1,199</b> |
| PPE & Testing Team                           | 54           | 54           | 54         | 54         | 54         | 54         | 54         | 54         | 54         | 54         | 54         | 54         | <b>646</b>   |
| OOA Beds                                     | 373          | 373          | 280        | 187        | 93         | 93         | 0          | 0          | 0          | 0          | 0          | 0          | <b>1,399</b> |
| Additional staffing support                  | 775          | 581          | 387        | 387        | 194        | 194        | 0          | 0          | 0          | 0          | 0          | 0          | <b>2,518</b> |
| Additional cleaning                          | 70           | 70           | 70         | 70         | 70         | 70         | 70         | 70         | 70         | 70         | 70         | 70         | <b>834</b>   |
|  | <b>1,430</b> | <b>1,237</b> | <b>950</b> | <b>856</b> | <b>570</b> | <b>570</b> | <b>283</b> | <b>283</b> | <b>283</b> | <b>283</b> | <b>283</b> | <b>283</b> | <b>7,308</b> |

The Trust's retained Covid-19 funding is **£9.5m** of which **£7.3m** is retained to support:

- **£1.9m** Inpatient cost pressures
- **£1.5m** PPE & Testing Team and additional cleaning
- **£3.9m** additional ward staffing and OOA beds in line with current spend, tapering down on the assumption costs will reduce.

|                                       | Plan YTD M1   | Actual YTD    | Variance      |             | Actual YTD    | Change        |            |   |
|---------------------------------------|---------------|---------------|---------------|-------------|---------------|---------------|------------|---|
|                                       | FY23          | M1 FY23       | £'000         | %           | M1 FY22       | £'000         | %          |   |
| Block                                 | 33,956        | 33,893        | -63           | 0%          | 26,744        | 7,149         | 27%        | ① |
| Cost & Volume                         | 1,123         | 988           | -136          | -12%        | 1,062         | -74           | -7%        |   |
| Cost Per Case                         | 406           | 411           | 5             | 1%          | 449           | -38           | -9%        |   |
| CQUIN                                 | 279           | 279           | 0             | 0%          | 239           | 41            | 17%        |   |
| Local Authority                       | 2,127         | 2,578         | 451           | 21%         | 1,695         | 883           | 52%        | ② |
| Section 75 (pooled budget)            | 450           | 435           | -15           | -3%         | 452           | -17           | -4%        |   |
| Private Patients                      | 5             | 17            | 12            | 256%        | 11            | 7             | 61%        |   |
| <b>Clinical Income Total</b>          | <b>38,346</b> | <b>38,600</b> | <b>254</b>    | <b>1%</b>   | <b>30,651</b> | <b>7,949</b>  | <b>26%</b> |   |
| Education And Training                | 1,191         | 1,637         | 446           | 37%         | 1,278         | 359           | 28%        |   |
| Research & Development                | 797           | 887           | 90            | 11%         | 1,206         | -318          | -26%       |   |
| FRF/Top Up Payment                    | 0             | 1,364         | 1,364         | 0%          | 1,100         | 263           | 24%        | ① |
| Accommodation                         | 77            | 91            | 14            | 18%         | 49            | 42            | 84%        |   |
| Catering                              | 0             | 0             | 0             | 0%          | 0             | 0             | 0%         |   |
| Non-Patient Care to Other Bodies      | 93            | 115           | 22            | 24%         | 128           | -13           | -10%       |   |
| Other Income                          | 160           | 161           | 1             | 0%          | -89           | 250           | 281%       |   |
| Parking                               | 6             | 0             | -6            | -100%       | 0             | 0             | 0%         |   |
| Oxford Pharmacy Sales                 | 2,584         | 2,551         | -33           | -1%         | 1,828         | 723           | 40%        | ③ |
| <b>Other Operating Income Total</b>   | <b>4,908</b>  | <b>6,805</b>  | <b>1,897</b>  | <b>39%</b>  | <b>5,501</b>  | <b>1,304</b>  | <b>24%</b> |   |
| Permanent                             | 25,769        | 21,436        | 4,333         | 17%         | 19,924        | -1,512        | -8%        | ④ |
| Flexible                              | 434           | 2,471         | -2,037        | -469%       | 1,897         | -575          | -30%       | ⑤ |
| Agency                                | 2             | 5,572         | -5,570        | -283034%    | 4,180         | -1,392        | -33%       | ⑥ |
| <b>Employee Benefits Expenses</b>     | <b>26,205</b> | <b>29,479</b> | <b>-3,274</b> | <b>-12%</b> | <b>26,001</b> | <b>-3,478</b> | <b>13%</b> |   |
| Clinical Services & Supplies          | 1,462         | 1,883         | -421          | -29%        | 784           | -1,099        | 140%       | ⑦ |
| Drugs                                 | 2,719         | 2,729         | -10           | 0%          | 2,005         | -724          | 36%        | ⑧ |
| PFI                                   | 49            | 79            | -30           | -62%        | 32            | -48           | 150%       |   |
| Car Park Security                     | 0             | 0             | 0             | 0%          | 0             | 0             | 0%         |   |
| Premises And Fixed Plant              | 1,117         | 1,598         | -480          | -43%        | 699           | -899          | 129%       | ⑨ |
| Premises - Business Rates             | 113           | -22           | 135           | 119%        | 123           | 145           | -118%      |   |
| Secondary Commissioning               | 0             | 0             | 0             | 0%          | 0             | 0             | 0%         |   |
| Purchase Of Healthcare                | 6,159         | 5,803         | 356           | 6%          | 3,300         | -2,503        | 76%        | ⑩ |
| Establishment Expenditure             | 629           | 547           | 83            | 13%         | 439           | -108          | 25%        |   |
| Insurance                             | 41            | 35            | 6             | 15%         | 45            | 10            | -23%       |   |
| Audit Fees External                   | 7             | 5             | 2             | 34%         | 5             | 0             | 1%         |   |
| Audit Fees Internal                   | 8             | 8             | 0             | 5%          | 4             | -4            | 87%        |   |
| Clinical Negligence                   | 69            | 88            | -19           | -27%        | 83            | -5            | 6%         |   |
| Consultancy                           | 6             | 29            | -23           | -418%       | -20           | -49           | -242%      |   |
| General Supplies And Services         | 213           | 233           | -21           | -10%        | 271           | 37            | -14%       |   |
| Legal Fees                            | 19            | 25            | -6            | -29%        | 24            | 0             | 1%         |   |
| Losses And Special Payments           | 2             | 1             | 0             | 9%          | 1             | -1            | 115%       |   |
| NHS Services                          | 0             | 0             | 0             | 0%          | 0             | 0             | 0%         |   |
| Other Non-Pay Expenditure             | 1,925         | 869           | 1,056         | 55%         | 927           | 57            | -6%        | ③ |
| Other Services                        | 47            | 33            | 14            | 30%         | 20            | -13           | 67%        |   |
| Patient Travel                        | 0             | 0             | 0             | 0%          | 0             | 0             | 0%         |   |
| Provisions                            | 5             | 49            | -44           | -941%       | 46            | 0             | 0%         |   |
| Redundancy Costs                      | 0             | 0             | 0             | 0%          | 0             | 0             | 0%         |   |
| Training & Conferences                | 149           | 116           | 33            | 22%         | 92            | -24           | 26%        |   |
| Transport - Business Travel           | 323           | 59            | 263           | 82%         | 150           | 91            | -60%       |   |
| Transport - Other                     | 195           | 232           | -37           | -19%        | 129           | -104          | 81%        |   |
| Inventory Dhsc Covid Response         | 0             | 0             | 0             | 0%          | 0             | 0             | 0%         |   |
| <b>Total Other Operating Expenses</b> | <b>15,257</b> | <b>14,400</b> | <b>857</b>    | <b>6%</b>   | <b>9,157</b>  | <b>-5,240</b> | <b>57%</b> |   |
| <b>EBITDA Total</b>                   | <b>1,793</b>  | <b>1,526</b>  | <b>-267</b>   | <b>-15%</b> | <b>994</b>    | <b>532</b>    | <b>54%</b> |   |

Please see next page for notes

## Performance against Plan

EBITDA is a **£1.5m** surplus, **£0.3m** adverse to plan at month 1 The main drivers of the position are:

1. FRF/Top up Payment **£1.4m** favourable – this is the retrospective top up payments for Covid-19 costs which are not part of the Covid-19 allocation. **£1.4m** is for the costs of running the vaccination sites.
2. Employee Benefits Expenses (Pay) **£3.3m** adverse - **£1.4m** of this is due to staff at the mass vaccination centres . Continuation of high level of agency (**c.£1.2m**) reported as Covid spend in FY22 partially mitigated by release of covid funding **c.£0.6m** in expectation of the tapering down of these expenditure items. Medical staffing **£0.8m** adverse exacerbated by high agency usage, CIP under delivery **£0.4m** and other **£0.1m** adverse.
3. Other Non-Pay Expenditure **£1.7m** favourable – release of reserves to support position.


## Performance against Prior Year

The EBITDA position is **£0.5m** better than last financial year. The significant changes from FY21 are:

1. Block income is **£7.1m** higher than last year due inflation **£0.5m**; full year effect of secure and AED provider collaboratives **£5.5m**; other driven by investments **£1.1m**.
2. Local Authority income is **£0.9m** higher than last year due to inflation and Oxfordshire County Council prior year inflation accounted for in FY23.
3. Increase in OPS sales post Covid **£0.7m**.
4. Permanent staff costs have increased by **£1.5m** from last year, due to **£0.6m** FY22 inflation; new costs in Oxfordshire & BSW MH and Buckinghamshire MH directorates as a result of investment in these services last year **£0.6m**; **£0.2m** FY23 increase in employers NI, **£0.1m** across other services.
5. Flexible staff costs have increased by **£0.6m** from last year, £0.2m each across Oxfordshire & BSW MH, Community and Specialised directorates.
6. Agency staff costs have increased by **£1.4m** from last year, new costs in Oxfordshire & BSW MH and Buckinghamshire MH directorates as a result of investment in these services last year **£1.1m**; Other **£0.3m** including **£0.2m** Covid-19.
7. Clinical Service & Supplies are **£1.1m** higher than last year due to the continuing care placements services in the Community directorate.
8. Drugs are **£0.7m** higher than last year due to higher sales in OPS post Covid-19
9. Premises and Fixed Plant costs are **£0.9m** higher than last year due to a category change with Secondary Commissioning costs.
10. Purchase of Healthcare **£2.5m** higher than last year due to provider collaborative in particular full year effect of Secure and change in lead provider payment regime.

## Out of Area Treatments (OATs)

OATs are **£485k** overspent at month 1 (**£447k** overspend in Oxfordshire and **£38k overspend** in Buckinghamshire). This includes the costs of a 16 bed contract with Elysium Potter Bar, that was recharged to COVID in FY22. An additional 5 Beds that Oxon hold on another Contract with Elysium Chadwick Lodge.





## Variance to Plan by Month

| <b>PLAN</b>                     | <b>Month 1</b> |             |
|---------------------------------|----------------|-------------|
|                                 | <b>£m</b>      |             |
| Clinical Income                 |                | 38.3        |
| Other Operating Income          |                | 4.9         |
| <b>Operating Income Total</b>   |                | <b>43.3</b> |
| Employee Benefits Expenses      |                | 26.2        |
| Other Operating Costs           |                | 15.3        |
| <b>Operating Expenses Total</b> |                | <b>41.5</b> |
| <b>EBITDA</b>                   |                | <b>1.8</b>  |
|                                 |                |             |
| <b>ACTUAL</b>                   | <b>Month 1</b> |             |
|                                 | <b>£m</b>      |             |
| Clinical Income                 |                | 38.6        |
| Other Operating Income          |                | 6.8         |
| <b>Operating Income Total</b>   |                | <b>45.4</b> |
| Employee Benefits Expenses      |                | 29.5        |
| Other Operating Costs           |                | 14.4        |
| <b>Operating Expenses Total</b> |                | <b>43.9</b> |
| <b>EBITDA</b>                   |                | <b>1.5</b>  |
|                                 |                |             |
| <b>VARIANCE</b>                 | <b>Month 1</b> |             |
|                                 | <b>£m</b>      |             |
| Clinical Income                 |                | 0.3         |
| Other Operating Income          |                | 1.9         |
| <b>Operating Income Total</b>   |                | <b>2.2</b>  |
| Employee Benefits Expenses      | -              | 3.3         |
| Other Operating Costs           |                | 0.9         |
| <b>Operating Expenses Total</b> | -              | <b>2.4</b>  |
| <b>EBITDA</b>                   | -              | <b>0.3</b>  |

## 2. Clinical Income

| CLINICAL INCOME                           | YTD at month 1 |                 |                   |               |
|---|----------------|-----------------|-------------------|---------------|
|   | Plan<br>£'000  | Actual<br>£'000 | Variance<br>£'000 | Variance<br>% |
| Any Qualified Provider                    | 296            | 296             | (0)               | 0%            |
| Bath & NE Somerset Block                  | 0              | 0               | 0                 | 0%            |
| Berkshire Block                           | 16             | 16              | 0                 | 0%            |
| Buckinghamshire Block                     | 4,627          | 4,534           | (92)              | -2% ①         |
| Buckinghamshire Block - IAPT              | 0              | 0               | 0                 | 0%            |
| Buckinghamshire County Council            | 833            | 833             | (0)               | 0%            |
| Buckinghamshire S75 (pooled budget)       | 299            | 284             | (15)              | -5%           |
| Cost per Case Income                      | 105            | 111             | 6                 | 6%            |
| CQUIN provision                           | 0              | 0               | 0                 | 0%            |
| Department of Health & Social Care        | 0              | 0               | 0                 | 100%          |
| Income from NHS Trusts                    | 157            | 168             | 11                | 7%            |
| Nene Block                                | 0              | 0               | 0                 | 0%            |
| NHS BSW                                   | 1,480          | 1,495           | 15                | 1%            |
| NHS England Block                         | 10,127         | 9,972           | (155)             | -2% ②         |
| NHS England Cost & Volume                 | 97             | 62              | (36)              | -37%          |
| NHS England New Care Models               | 0              | 0               | 0                 | 0%            |
| NHS England FCAMHS                        | 94             | 94              | (0)               | 0%            |
| NHS Northamptonshire                      | 51             | 80              | 29                | 57%           |
| Other CCGs Income                         | 2              | 32              | 30                | 1771%         |
| Other Local Authority                     | 3              | 1               | (2)               | -79%          |
| Oxfordshire Block - IAPT                  | 858            | 858             | 0                 | 0%            |
| Oxfordshire Block - Learning Disabilities | 606            | 629             | 23                | 4%            |
| Oxfordshire Block - main contract         | 10,363         | 10,173          | (190)             | -2% ③         |
| Oxfordshire Block - OBC                   | 4,930          | 5,085           | 155               | 3% ④          |
| Oxfordshire Block - CAMHS                 | 1,247          | 1,257           | 10                | 1%            |
| Oxfordshire Cost & Volume                 | 623            | 623             | 0                 | 0%            |
| Oxfordshire County Council                | 1,247          | 1,700           | 453               | 36% ⑤         |
| Oxfordshire S75 (pooled budget)           | 150            | 150             | 0                 | 0%            |
| Personal Injury Compensation              | 9              | 8               | (2)               | -16%          |
| Private Patients                          | 5              | 17              | 12                | 256%          |
| Swindon Block                             | 0              | 0               | 0                 | 0%            |
| Wales Cost & Volume                       | 77             | 77              | 0                 | 0%            |
| Wiltshire Block                           | 0              | 0               | 0                 | 0%            |
| Wiltshire Borough Council                 | 43             | 43              | 0                 | 0%            |
| <b>Clinical Income Total</b>              | <b>38,346</b>  | <b>38,600</b>   | <b>254</b>        | <b>1%</b>     |

Clinical income is **£254k** favourable to plan at month 1. Material variances to the plan are:



1. Bucks Block is **£92k** adverse – received income less than plan.
2. NHS England Block - **£155k** adverse underperformance Forensic and AED I/P services.
3. Oxfordshire Block main contract - **£190k** adverse received income less than plan.
4. Oxfordshire OBC - **£155k** release of b/f income.
5. Oxfordshire County Council - **£453k** favourable prior year inflation accounted for in FY23.

### 3. Non-Clinical Income

| NON-CLINICAL INCOME               | YTD at month 1 |                 |                   |               |
|-----------------------------------|----------------|-----------------|-------------------|---------------|
|                                   | Plan<br>£'000  | Actual<br>£'000 | Variance<br>£'000 | Variance<br>% |
| Education & Training              | 1,191          | 1,637           | 446               | 37%           |
| Other Operating Income            | 2,920          | 4,281           | 1,361             | 47%           |
| Research & Development            | 797            | 887             | 90                | 11%           |
| <b>Non- Clinical Income Total</b> | <b>4,908</b>   | <b>6,805</b>    | <b>1,897</b>      | <b>39%</b>    |

- Education & Training income **£446k** favourable. OTH unbudgeted income matched to spend **£95k**. **£129k** Apprenticeship income received for trainees matching pay expenditure. The balance is due to training income received in central L&D & FY22 deferred income releases for fixed term staff. HEE income for trainees in IAPT and CAMHS **£167k**; other **£55k**
- Other Operating Income **£1,364k** favourable due to retrospective top up payments for the costs of the mass vaccination centres; **£3k** other
- Research & Development income is **£90k** favourable budget profile not yet finalised offset in expenditure.

## 4. Agency



At month 1 **£4.3m** has been spent on agency staff, which is **15.2%** of total staff costs. This includes **£1.3m** of agency spend in the Covid-19 vaccination centres. Note that the graphs above exclude spend in the Covid-19 vaccination centres to show a normalised position.

Please refer to the HR report for further details.

## 5. Cost Improvement Plan

| CIP / PIP Delivery at Month 01 FY23 |              |              |            |            |              |              |                   |
|-------------------------------------|--------------|--------------|------------|------------|--------------|--------------|-------------------|
| Projects                            | FY Target    | FY Plan      | YTD Plan   | YTD Actual | YTD Variance | Forecast     | Forecast Variance |
|                                     | £'000        | £'000        | £'000      | £'000      | £'000        | £'000        | £'000             |
| CIP Programme                       | 7,929        | 3,144        | 661        | 169        | -491         | 2,033        | -5,896            |
| PIP Schemes / Agency Reduction      | 0            | 1,345        | 0          | 109        | 109          | 1,309        | 1,309             |
| Covid Costs Reduction               | 0            | 0            | 0          | 0          | 0            | 0            | 0                 |
| <b>Total</b>                        | <b>7,929</b> | <b>4,490</b> | <b>661</b> | <b>279</b> | <b>-382</b>  | <b>3,342</b> | <b>-4,587</b>     |

- The FY23 CIP Target is **£7.9m** phased evenly across FY23.
- The savings as at the end of month 1 are **£0.3m**: **£0.2m** corporate efficiencies; **£0.1m** IQRA programme.
- The YTD and forecast savings are **£0.4m** & **£4.6m** adverse to target respectively. The primary reason for this is delay in CIP engagement due to Covid.

## 6. Statement of Financial Position

| Statement of Financial Position as at 30th April 2022 |                                      |                  |                  |                 |              |
|---|--------------------------------------|------------------|------------------|-----------------|--------------|
| 31 March<br>2022                                      |                                      | Month 13<br>FY22 | Month 1<br>FY23  | Movement        |              |
|   |                                      |                  |                  | Year to<br>date |              |
| £'000   |                                      | £'000            | £'000            | £'000           |              |
|   |                                      |                  |                  | In<br>month     |              |
|   |                                      |                  |                  | £'000           |              |
| <b>Non-current assets</b>                             |                                      |                  |                  |                 |              |
| 6,390   | Intangible Assets                    | 6,390            | 6,093            | (298)           | (298)        |
| 155,907   | Property, plant and equipment        | 155,907          | 155,627          | (280)           | (280)        |
| 487   | Trade and other receivables          | 487              | 499              | 12              | 12           |
| <b>162,784</b>  | <b>Total non-current assets</b>      | <b>162,784</b>   | <b>162,219</b>   | <b>(566)</b>    | <b>(566)</b> |
| <b>Current Assets</b>                                 |                                      |                  |                  |                 |              |
| 2,003   | Inventories                          | 2,003            | 1,731            | (272)           | (272)        |
| 19,702  | Trade and other receivables          | 19,702           | 25,330           | 5,628           | 5,628        |
|   | Non-current assets held for sale     | 0                | 0                | 0               | 0            |
| 89,517  | Cash and cash equivalents            | 89,517           | 84,578           | (4,939)         | (4,939)      |
| <b>111,223</b>  | <b>Total current assets</b>          | <b>111,223</b>   | <b>111,639</b>   | <b>416</b>      | <b>416</b>   |
| <b>Current Liabilities</b>                            |                                      |                  |                  |                 |              |
| (75,128)  | Trade and other payables             | (75,128)         | (72,315)         | 2,813           | 2,813        |
| (2,817)   | Borrowings                           | (2,817)          | (2,870)          | (53)            | (53)         |
|   | Other financial liabilities          | 0                | (1,788)          | (1,788)         | (1,788)      |
| (2,473)   | Provisions                           | (2,473)          | (2,476)          | (3)             | (3)          |
| (22,784)  | Deferred income                      | (22,784)         | (22,911)         | (127)           | (127)        |
| <b>(103,203)</b>                                      | <b>Total Current Liabilities</b>     | <b>(103,203)</b> | <b>(102,361)</b> | <b>842</b>      | <b>842</b>   |
| <b>Non-current Liabilities</b>                        |                                      |                  |                  |                 |              |
|   | Trade and other payables             | 0                | 0                | 0               | 0            |
| (15,784)  | Borrowings                           | (15,784)         | (15,734)         | 50              | 50           |
| (4,524)   | Provisions                           | (4,524)          | (4,548)          | (24)            | (24)         |
| (1,132)   | Other Liabilities                    | (1,132)          | (1,132)          | 0               | 0            |
| <b>(21,440)</b>                                       | <b>Total non-current liabilities</b> | <b>(21,440)</b>  | <b>(21,414)</b>  | <b>26</b>       | <b>26</b>    |
| <b>149,364</b>  | <b>Total assets employed</b>         | <b>149,364</b>   | <b>150,083</b>   | <b>719</b>      | <b>719</b>   |
| <b>Financed by (taxpayers' equity)</b>                |                                      |                  |                  |                 |              |
| 107,619   | Public Dividend Capital              | 107,619          | 107,619          | 1               | 1            |
| 27,469  | Revaluation reserve                  | 27,469           | 27,471           | 1               | 1            |
|   | Other reserves                       | 0                | 0                | 0               | 0            |
| 14,276  | Income & expenditure reserve         | 14,276           | 14,993           | 717             | 717          |
| <b>149,364</b>  | <b>Total taxpayers' equity</b>       | <b>149,364</b>   | <b>150,083</b>   | <b>720</b>      | <b>720</b>   |

1. Non-current assets have decreased by **£0.6m** in-month due largely due to the in-month depreciation charge.
2. Trade and other receivables have increased by **£5.6m** in month in line with net cash inflows, **£2.9m** in prepayments and **£3.7m** in accrued income.
3. Cash has decreased by **£4.9m**. Most of this, **£4.5m**, can be attributed the payment capital creditors brought forward from FY22.
4. Trade and other payables have decreased by **£2.8m** in the month. The decrease is in line with the net cash outflows and is due mainly to a decrease in payables and accruals of **£2.3m**.
5. Deferred income has increased marginally in M1 by **£0.1m**.
6. Borrowings have decreased by **£50k** in the month in line with the expected decrease in the Trust's PFI liability.
7. The **£0.7m** in-year increase in the I&E reserve reflects the Trust's reported surplus in month.

## 7. Cash Flow

### STATEMENT OF YEAR TO DATE CASH FLOWS

|   | Month 1 FY23    |                |                   |
|---|-----------------|----------------|-------------------|
|   | Actual<br>£'000 | Plan<br>£'000  | Variance<br>£'000 |
| <b>Cash flows from operating activities</b>                           |                 |                |                   |
| Operating surplus/(deficit) from continuing operations                | 1,023           | 54             | 969               |
| Operating surplus/(deficit) from discontinuing operations             | 0               | 0              | 0                 |
| <b>Operating surplus/(deficit)</b>                                    | <b>1,023</b>    | <b>54</b>      | <b>969</b>        |
| <b>Non-cash income and expense:</b>                                   |                 |                |                   |
| Depreciation and amortisation   | 503             | 950            | (447)             |
| Impairments and profit on disposal of assets                          | 0               | 0              | 0                 |
| Income recognised in respect of capital donations (cash and non-cash) | 0               | 0              | 0                 |
| (Increase)/Decrease in Trade and Other Receivables                    | (5,772)         | 1,748          | (7,519)           |
| (Increase)/Decrease in Inventories                                    | 272             | 281            | (9)               |
| Increase/(Decrease) in Trade and Other Payables                       | 1,279           | (2,579)        | 3,858             |
| Increase/(Decrease) in Deferred Income                                | 1,915           | (500)          | 2,415             |
| Increase/(Decrease) in Provisions                                     | 27              | 0              | 27                |
| Other Movements in Operating Cashflows                                | 0               | 0              | 0                 |
| <b>NET CASH GENERATED FROM/(USED IN) OPERATION:</b>                   | <b>(753)</b>    | <b>(47)</b>    | <b>(706)</b>      |
| <b>Cash flows from investing activities</b>                           |                 |                |                   |
| Interest received   | 49              | 23             | 26                |
| Purchase of Non Current Assets  | (4,236)         | (4,489)        | 253               |
| Sale of PPE   | 0               | 0              | 0                 |
| <b>Net cash generated from/(used in) investing activities</b>         | <b>(4,187)</b>  | <b>(4,466)</b> | <b>279</b>        |
| <b>Cash flows from financing activities</b>                           |                 |                |                   |
| Public dividend Capital Received                                      | 0               | 0              | 0                 |
| Loans received  | 0               | 0              | 0                 |
| Loans repaid  | 0               | 0              | 0                 |
| Capital element of lease rental payments                              | 0               | (445)          | 445               |
| Capital element of Private Finance Initiative Obligations             | 0               | 0              | 0                 |
| Interest paid   | (0)             | 0              | (0)               |
| Interest element on leases  | 0               | (21)           | 21                |
| Interest element of Private Finance Initiative obligations            | 0               | 0              | 0                 |
| PDC Dividend paid   | 0               | 0              | 0                 |
| <b>Net cash generated from/(used in) financing activities</b>         | <b>(0)</b>      | <b>(466)</b>   | <b>466</b>        |
| <b>Increase/(decrease) in cash and cash equivalents</b>               | <b>(4,939)</b>  | <b>(4,979)</b> | <b>39</b>         |
| <b>Cash and Cash equivalents at 1st April</b>                         | <b>89,517</b>   | <b>89,517</b>  | <b>0</b>          |
| <b>Cash and Cash equivalents at 30th April</b>                        | <b>84,578</b>   | <b>84,539</b>  | <b>39</b>         |

### Summary Notes

- The cash flow movements are consistent with the comments made on the Statement of Financial Position.
- The closing cash position at Month 1 was **£84.6m**.

## 8. Working Capital Indicators

| Working Capital Ratios                               |        |        |             |
|--|--------|--------|-------------|
| Ratio  | Target | Actual | Risk Status |
| Debtor Days  | 30     | 37     | ●           |
| Debtors % > 90 days                                  | 5.0%   | 18.2%  | ●           |
| Creditor Days  | 30     | 46     | ●           |
| BPPC NHS - Value of Inv's pd within target (ytd)     | 95.0%  | 97.4%  | ●           |
| BPPC Non-NHS - Value of Inv's pd within target (ytd) | 95.0%  | 83.9%  | ●           |
| Cash (£m)  | 72.0   | 84.6   | ●           |

### Summary Notes

- Debtor days at month 1 below target.
- Debtors % over 90 days below target due to overdue invoices: NHSE £451k, Ox CCG £443k
- The Creditor days position is below plan due to high level of accruals for NHS and Non-NHS suppliers and the impact of the BPPC figures
- NHS BPPC is above target in M1
- Non-NHS BPPC is below target in M1
- Cash is better than target, as outlined in section 7 and 8.



## 9. Capital Investment Programme

| Estates & IM&T Committed FY23 Projects          | Committed<br>£'000 | Notes   |
|---|--------------------|---|
| Project c/f                                     | 1,117              |   |
| Warneford Campus                                | 830                |   |
| GAU (MH Swindon)                                | 551                | Increase cost against plan - £ RISK   |
| picu + highfield hdu suite                      | 6,474              | Reclaim 5% VAT (£324k), potential for 20% Residency Status, additional saving 15% (£810k) Completion Mar 23 |
|   | <b>8,972</b>       |   |
| EPMA  | 431                |   |
| True Colours                                    | 200                |   |
|   | <b>631</b>         |   |
| Medical Equipment c/f                           | 300                |   |
| <b>Committed Projects FY23</b>                  | <b>9,903</b>       |   |
|   |                    |   |
| <b>ICS Capital Programme Fund FY23</b>          | <b>9,900</b>       |   |
| Shrublands Sale (NBV)                           | 682                | Completion of Sale by Mar 23  |
| Harlow Sale (NBV)                               | 700                | Completion of Sale by Mar 23  |
| Approx (Accrual/VAT reclaim)                    | 1,000              | Approx Figure £   |
| <b>Total Capital Programme Fund FY23</b>        | <b>12,282</b>      |   |
| <b>Available funding</b>                        | <b>2,379</b>       |   |
|   |                    |   |
| <b>Potential Revenue Costs</b>                  |                    |   |
| Digital Aspirants - Match Funding               | 1,000              | UTF Match Funding   |
| Enabling Digital Infrastructure - Match Funding | 300                | UTF Match Funding   |
| End User Devices - Match Funding                | 385                | UTF Match Funding   |
| Networks - Match Funding                        | 327                | UTF Match Funding   |
| Project c/f IM&T (tablets)                      | 300                |   |
| Integration                                     | 140                |   |
|   | <b>2,452</b>       |   |

- The FY23 draft capital plan totals **£12.2m**. The detailed capital plan is currently at the approval stage with Exec's and CPSC.

## 10. Reconciliation to NHSE/I Template

The financial figures reported in this report are taken directly from the finance ledger. The financial figures reported to NHSE/I each month differ from these figures as they exclude income and costs related to the Section 75 pooled budget and are some minor adjustments to the categories certain items are reported under. The table below provides a reconciliation between the figures reported in this board report to the figures reported on the NHSI template.

| YTD Actuals at month 1 FY23      |              |                                       |                     |                             |               |             |
|----------------------------------|--------------|---------------------------------------|---------------------|-----------------------------|---------------|-------------|
|                                  | Board Report | Remove Section 75<br>Income and Costs | Category<br>Changes | National<br>supplied<br>PPE | NHSI Template |             |
|                                  | £m           | £m                                    | £m                  | £m                          | £m            | £m          |
| Clinical Income                  | 38.6         | -3.9                                  |                     |                             |               | 34.7        |
| Other Operating Income           | 6.8          |                                       |                     |                             |               | 6.8         |
| <b>Operating Income, Total</b>   | <b>45.4</b>  | <b>-3.9</b>                           | <b>0.0</b>          | <b>0.0</b>                  |               | <b>41.6</b> |
| Employee Benefit Expenses (Pay)  | 29.5         | -3.6                                  |                     |                             |               | 25.9        |
| Other Operating Expenses         | 14.4         | -0.2                                  |                     |                             |               | 14.2        |
| <b>Operating Expenses, Total</b> | <b>43.9</b>  | <b>-3.9</b>                           | <b>0.0</b>          | <b>0.0</b>                  |               | <b>40.0</b> |
| Non-Operational Income           |              |                                       |                     |                             |               | 0.0         |
| <b>EBITDA</b>                    | <b>1.5</b>   | <b>0.0</b>                            | <b>0.0</b>          | <b>0.0</b>                  |               | <b>1.5</b>  |
| Profit/(Loss) on asset disposal  | 0.0          |                                       |                     |                             |               | 0.0         |
| Depreciation and Amortisation    | 0.5          |                                       |                     |                             |               | 0.5         |
| Asset Impairment                 | 0.0          |                                       |                     |                             |               | 0.0         |
| Interest                         | 0.0          |                                       |                     |                             |               | 0.0         |
| Other Finance Charge             | 0.1          |                                       |                     |                             |               | 0.1         |
| PDC Dividend                     | 0.2          |                                       |                     |                             |               | 0.2         |
| <b>Surplus/ (Deficit)</b>        | <b>0.7</b>   | <b>0.0</b>                            | <b>0.0</b>          | <b>0.0</b>                  |               | <b>0.7</b>  |